☆ 4.2 Article

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2021)

Related references

Note: Only part of the references are listed.

Letter Immunology

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

Rossella Talotta

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Medicine, General & Internal

Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?

Soren Dinesen Ostergaard et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Kate-Lynn Muir et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

Related references

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Export Citation

Share Paper